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ABSTRACT 
 
Intestinal health and the maintaining the integrity of the intestinal barrier 
are critical to maintaining overall health.  Research conducted over the years has 
consistently shown an unhealthy gut is detrimental to one’s overall well-being 
and is associated with a number of disease states including obesity, autism, 
Inflammatory bowel disease, and other autoimmune disorders.  Chronic intestinal 
inflammation is an innate immune response that can disrupt the intestinal barrier 
causing it to become leaky and leaving the host susceptible to a plethora of 
environmental pathogens.  Inflammation is also an energy draining physiological 
process that also causes health complications. 
Consumption of nonstarch polysaccharides, such as the guar gum 
containing β-galactomannan, have been shown to stimulate the innate immune 
response characterized by high levels of inflammatory cytokines.  In livestock, 
studies have regularly shown the negative side effects of soybean meal β-
galactomannan on health and immune function including impaired nutrient 
absorption, stunted growth, and inflammation.  In vivo studies have also 
elucidated the immunostimulatory effects of mannans.   Gums containing β-
galactomannan are commonly used as thickeners, stabilizers, and binders in 
food industry.  Therefore, it is essential to elucidate the extent of inflammation β-
galactomannan may cause in order to protect the health of consumers.  
 Our study was conducted to further characterize the impact of guar 
gum derived β-galactomannan on health and immune status in Sprague-Dawley 
 	   x	  
rats.  As expected, rats fed β-galactomannan gained less weight throughout the 
course of the study compared to control rats and also consumed less.  These 
effects, however, were not accompanied by an increased inflammatory cytokine 
profile.  Β-galactomannan consumption did not affect inflammatory cytokines IL-
12a, IL-12b, or IL-6 nor did it affect the anti-inflammatory cytokine IL-10 in the 
ileum.  Even more perplexing was that in the jejunum, β-galactomannan 
increased IL-10 mRNA transcript abundance and decreased IL-12a mRNA 
levels.  Based on our experiment, β-galactomannan did not stimulate an innate 
immune response
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CHAPTER 1: LITERATURE REVIEW 
 
 
 
Introduction to Gut Immunology 
 
The gastrointestinal tract (GIT) functions to digest and absorb nutrients. 
However, because it is normally the first point of contact with microbes, it is also 
the largest immune organ in the body and plays a critical role in immune 
homeostasis. Upon exposure to pathogens, self-antigens, and dietary antigens, 
the GIT may mount either an immunogenic or tolerogenic response.1  Typically, 
interactions between gut-associated lymphoid tissue (GALT) and food promote 
oral tolerance of these dietary antigens  via anergy, deletion of T cells, or the 
induction of regulatory T cells.2  In fact, recent studies have investigated the 
induction of oral tolerance as a potential means of treating food allergies and 
other autoimmune disorders.3  Nonetheless, misdirected immune responses and 
impaired gut integrity may result in devastating gut related disorders, such as 
inflammatory bowel diseases (IBD) and food allergies which exacerbates 
disruptions in intestinal epithelial integrity.3  Gut health has also been linked to 
other disease pathologies such as chronic heart failure and autism.4,5  Oral 
tolerance involves anergy, deletion of T cells, or the induction of regulatory T 
cells.2 
 
Gastrointestinal architecture 
The small intestine is lined with villi, microvilli, and invaginations, also 
known as “crypts”. Villi are fingerlike projections, which increase surface area for 
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better absorption of nutrients and contain blood vessels to transport food 
systemically. The Lamina Propia (LP) of the villi is a layer of connective tissue 
just under the epithelium of the mucous membrane. Microvilli protrude from the 
enterocytes, or intestinal epithelial cells (IECs), collectively forming the brush 
border to further enhance nutrient absorption.  IECs are held together by tight 
junctions which function to prevent attachment and subsequent invasion of 
pathogenic microbes.6  The intestinal crypts function in cell replication, to 
replenish the epithelial layer, and in mucous production.  Throughout the 
intestinal mucosa, dome-like structures known as Payer’s patches are enriched 
with lymphoid tissue and are key sites for the development of tolerogenic and 
immunogenic responses.  Microfold cells, or M cells, are specialized epithelial 
cells that function in antigen uptake by cells within Payer’s patches. Lymphatics 
from both the Payer’s patch and LP drain into a mesenteric lymph node (MLN) 
where the majority of naïve T cells are activated to promote differentiation into 
effector T cells. Within the Payer’s patches, there is an array of immune cells 
including T cells, B cells, dendritic cells (DC), and Macrophages.  
Collectively, the immune system of the digestive tract is most often 
referred to as gut-associated lymphoid tissue, or GALT. The constant interaction 
between GALT, dietary antigens, and normal flora of the GIT promotes an 
environment characterized by sustained low-level inflammation.7  Environmental 
and genetic-based challenges against the protective epithelial barrier may 
increase intestinal permeability and disrupt inflammatory homeostasis in the GIT.  
Such challenges may result in aberrant immunological responses of pathological 
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significance.  In particular, food allergies are associated with compromised 
intestinal epithelium function and hypersensitive immune function.8,9  
 
Dendritic cells 
Dendritic cells are the major antigen presenting cells (APC) of the immune 
system that bridge innate and adaptive immunity.  Most DC subsets express 
pattern recognition receptors that recognize pathogen-associated molecular 
patterns (PAMPs). Upon antigen recognition, DCs are activated to produce 
cytokines, carry out phagocytosis of the pathogen, and migrate to the MLN for 
maturation. Failure of the DC to mature and migrate results in impaired 
differentiation of effector T cells.10  As surveillance cells, DCs can aggregate 
below M cells of the gut to detect invading pathogens that have crossed the 
epithelial barrier.  However, the majority of immature DCs reside in the lamina 
propria, and can be classified into two subsets: CD103+ DC and CX3CR1 DC.11   
The most discernable difference between these subsets of DCs is in their 
migratory ability. Upon activation by toll-like receptor (TLR) signaling, CD103+ 
DCs travel via the hymphatics to the MLN where antigen presentation induces 
differentiation of naïve T cells into specific effector T cells which is part of the 
adaptive immune response.  In contrast, the CX3CR1 subset is a residential DC 
population that is incapable of migration to MLN and has poor antigen 
presentation abilities.  Schulz et al.11 demonstrated clear migratory differences 
using fluorescent-labeled Dextran.  Mice in the R848 inflammatory group showed 
mobilized CD103+ DC in lymph vessels and no change in location of the 
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CX3CR1 DC.  Yrlid et al.12 also reported R848 signaling via TLRs enhanced 
migration of CD103+ DC from the lamina propria to MLN.  Increased expression 
of costimulatory molecules CD40 and CD86 upon activation and maturation was 
seen in CD103+DC but not in the CX3CR1 cells.11  Furthermore, CX3CR1 DCs 
failed to promote naïve T cell differentiation.  These recent findings indicate 
intestinal CX3CR1 DCs may only possess innate function and serve as the first 
line of defense in the gut.  
These subsets of DCs also differ in their physical functionality. CX3CR1 
DCs have the ability to extend their dendrites between enterocytes by opening 
tight junctions and in doing so, are able to directly sample luminal contents of the 
gut.13  These dendritic extensions can be detected under normal conditions and 
will multiply in the presence of bacterial species. 13,14 
 Pathogen associated molecular patterns of a pathogen can illicit an innate 
immune response and inflammation by binding to a pattern recognition receptor 
(PRR) on a dendritic cell or other innate leukocyte. Under steady state 
conditions, low-level inflammation is present and controlled without causing a 
pathological response. When intestinal DCs are stimulated by self-antigens, 
dietary antigens, or commensal microbes, production and secretion of anti-
inflammatory IL-10 to control proinflammatory stimuli and promote tolerance is 
enhanced. IL-10 produced by the DC itself has an autocrine effect by binding to 
IL-10 receptors and preventing DC maturation and subsequent release of IL-12.15  
Secretion of IL-10 by other innate leukocytes and Tregs also causes inhibition of 
DC maturation, and thus promote a tolerogenic environment. Harmless antigens 
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may also cause unnecessary intestinal inflammation and lead to impaired gut 
function and nutrient utilization.16,17  Proinflammatory cytokines such as IL-12, IL-
6 and TNF-α are produced and secreted by activated and matured dendritic 
cells. Therefore, it is imperative that DCs develop appropriate immune responses 
to stimuli.  Both IL-10 and IL-12 have been implicated in signaling adaptive 
immunity. IL-10 promotes Treg development while IL-12 leads to the 
development of effector T cells such as Th17, Th1, and Th2. 
 
 
 
Figure 1: Immature dendritic cells survey intestinal contents during steady state.  
If no inflammatory signals maturation does not occur and Tregs can be induced.  
Infection and inflammation causes DCs to mature and induce effector T cells.  If a 
DC matures in the presence of IL-10, TGF-β, and a tolerant microenvironment, 
maturation if altered the DC becomes tolerogenic, or modulated.  tDCs can cause 
anergy of T cells, apoptosis of T cells, or differentiation into IL-10 or TGF-β 
producing Tregs.  From Mahnke et al.76 
IL-12 IL-10 
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Regulatory T Cells 
Gershon and Kondo were the first to propose the hypothesis that a subset 
of T cells existed with a primary role in blunting rather than enhancing immune 
responses.18  Research surrounding the concept of “Suppressor” T cells, as they 
were originally named, came to an abrupt halt due to flaws in the initial 
experimental designs.  However, in the early-90’s, advanced molecular tools led 
scientists to again propose the concept of suppressor T-cells which were 
reintroduced as regulatory T- cells (Tregs).18  The Sakaguchi lab demonstrated the 
importance of Treg cells using a mouse model based on thymectomy to remove 
the site of natural Treg cell production.18  Thereafter, mice were reconstituted 
with all T cell subsets with or without Treg cells. The mice devoid of Treg cells 
presented with systemic autoimmune disease whereas their counterparts 
remained healthy. This early experiment has spawned much research on these 
immunosuppressive cells, but some mechanisms are still not clearly defined. 
Many researchers agree two classes of regulatory T cells exist: natural 
regulatory T cells (nTreg) and induced regulatory T cells (iTreg). nTreg cells 
(CD4+,CD25+,Foxp3+) are thought to be antigen specific and develop from 
naïve nTregs produced by the thymus.19 The issue of whether nTregs are innate 
in nature or antigen specific (adaptive) is still controversial.  Interactions between 
MHCII on the DC and the T- cell receptor on the surface of the naïve Treg cell 
leads to development and activation of nTreg cells. These cells are important in 
controlling low-level immune responses in the periphery where they are located.  
nTreg cells express CD25, also known as the α chain of the IL-2 receptor, and 
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Foxp3.6  Foxp3 is a transcription factor crucial for the induction, maintenance, 
and function of Treg cells.20  Mutations in the Foxp3 gene lead to impaired or 
incomplete Treg cell production causing Immune dysregulation 
polyendocrinpathy enteropathy X-linked Syndrome (IPEX), a rare but fatal 
systemic autoimmune disease.21  More than 80% of IPEX patients suffer from 
multiple autoimmune diseases including Irritable Bowel Syndrome (IBS), 
enteropathy, dermatitis, allergies, and Type 1 Diabetes Mellitus (T1DM) and 
ultimately die early in life.  nTreg cells also express CTLA-4 which is an inhibitory 
receptor that downregulates effector T-cell response and may also modulate DC 
function.22  Studies have shown that CTLA-4 blocking antibodies and CTLA-4 
deficient Treg cells attenuate suppression of effector T cells.23,24  Non-regulatory 
T-cells (CD4+,CD25-,Foxp3-) have very low levels of CD25 and will usually lack 
Foxp3, although this remains a topic of discussion among researchers. In the 
lymph node, upon exposure to an antigen via an APC and in combination with IL-
10 and TGF-β, the CD4+ cell differentiate into iTreg cells.25  iTreg will also be 
induced by tolerogenic DCs and cytokine IL-10 to express Foxp3 via TGF-β and 
CD25, making it difficult to determine whether a Treg cell originated from a naïve 
nTreg cell or was induced by APC and cytokines.  Therefore, it is believed the 
majority of antigen specific Tregs are iTreg cells.26,27 
 
The development of immune tolerance via Tregs 
Regulatory T cells have the ability to promote immune tolerance via 
multiple mechanisms, including inhibitory cytokine production, direct disruption of 
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effector T-cells, modulation of dendritic cells, and cytolysis.  These distinct 
mechanisms, which can become redundant, are all required for maximal Treg 
cell function.22 
 
Production of inhibitory cytokine IL-10 
Cytokines are small proteins produced by host cells, particularly 
leukocytes. These signaling molecules can be characterized as pro-inflammatory 
or inhibitory (anti-inflammatory).  Upon exposure to an antigen, 
CD4+CD25+Foxp3+ Treg cells will produce and secrete cytokines IL-10 ad TGF-
β.19  IL-10 protects the host by limiting inflammatory responses and inducing 
tolerogenic DCs by limiting IL-12 production.28  Treg cell depletion of IL-10 
expression increases both lung allergic inflammation and hypersensitivity.29   IL-
10 produced by regulatory T-cells is also essential in preventing irritable bowel 
disease (IBD).22  Although IL-10 is not the only mechanism by which Tregs can 
dampen immune responses, it has been consistently linked to Treg activation.  
Present literature supports the hypothesis that IL-10 from Treg cells is dependent 
on both the organism itself and the disease state of the host.  IL-35 is another 
inhibitory cytokine thought to be required for maximal Treg cell function but the 
implications of IL-35 are still unclear.30 
 
Disruption of effector T-cells (CD4+) 
 Regulatory T cells can directly suppress target effector T cells that elicit an 
inflammatory immune response in the host.  As mentioned previously, Tregs 
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express CD25, the IL-2 receptor α chain, which can drive “cytokine deprivation 
mediated apoptosis”. CD25 supports local IL-2 consumption by Tregs which 
starves developing effector T cells that are dependent on IL-2 for survival.31,32  
However, this mechanism is still vigorously debated and a final consensus 
opinion will require additional research. 
 Treg cells release adenosine by converting ATP to AMP via 
ectonucleotidases CD39 and CD73.33  Ligation between adenosine and the A2a 
receptor present on effector T cells results in a signal transduction pathway 
upregulating second messenger cAMP concentrations.34,35  Elevated intracellular 
levels of cAMP suppresses the immunogenic activity of effector T cells.  
Additionally, adenosine may indirectly suppress effector T cells through 
modulation of DC maturation and the promotion of a tolerogenic phenotype. 
Regulatory T cells may also increase intracellular cAMP concentrations by 
transferring adenosine through gap junctions of effector T cells.36  As with other 
mechanisms, additional studies are required to support and extend existing data 
regarding this particular mechanism before it is viewed as a bona fide action of 
Tregs.   
Not only does the adenosine-A2a receptor complex effect effector T cell 
functioning, it has also been shown to suppress production of the 
proinflammatory IL-6. 37  IL-6 is essential for preventing Treg generation and 
inducing differentiation of CD4+ naïve T cells into proinflammatory Th17 cells.38  
If  an imbalance occurs and Th17 outweighs Tregs, the local host environment 
will favor an immunogenic response rather than promoting tolerance. This 
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inflammatory response is necessary for riding the host of pathogens but is 
unnecessary, and detrimental, when dealing with dietary antigens, self-antigens, 
and commensal microbiota. 
 
Modification of dendritic cells 
Although mediating the immune response by direct interaction with 
effector T cells is beneficial, Tregs often do so through DC mechanisms.  Tregs 
can condition DCs by interactions between CTLA4 and dendritic cell CD80 
and/or CD86. Upon contact, expression of indoleamine 2,3-dioxygenase (IDO) is 
upregulated and acts as a strong regulatory molecule by inducing the catabolism 
of tryptophan into apoptotic metabolites which can suppress effector T cells.39,40  
Tregs also possess the ability to directly downregulate expression of CD80 and 
CD86 on DC.41 Abberant expression of these costimulatory molecules leads to 
unresponsive, or anergic, effector T cells.42  
 
Promotion of cytolysis 
The final way Tregs promote tolerance is by deleting antigen specific T 
cells, thus eliminating an unwarranted immunogenic response against harmless 
antigens. Perforin and granzyme produced by Tregs are packaged into granules 
and released to induce apoptosis of effector T cells.43  Perforin disrupts the cell 
membrane while granzyme, a protease, affects cellular proteins. Fas ligand, used 
by iTregs, also promotes apoptosis of effector T cells.44 
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The preceding modes of action of Tregs lead to immune tolerance by 
promoting: (i) Suppression of immune cells, (ii) deletion of effector T cells and/or 
(iii) anergy also called immune unresponsiveness.19   Depending on the situation 
a specific mechanism will be used to suppress immunogenic responses.45 It is 
crucial to retain a balance between Tregs and effector T cells. When the 
appropriate ratio is disrupted and effector T cells, such as Th17 or Th1, in the 
gut, become the majority, immune responses will produce inflammation. 
Conversely, an unbalanced tolerogenic environment diluted by Tregs would 
leave the host susceptible to harmful pathogens. 
 
β-Galactomannan 
 β-Galactomannan (β-GM) is a non-starch polysaccharide (NSP) fiber 
shown to have adverse effects on the digestion and absorption of other nutrients, 
most likely due to its ability to impair the epithelial barrier function.46  The anti-
nutritive effects associated with β-galactomannan may be secondary to its 
activation of inflammatory immune responses.47   Structurally, galactomannans 
consist of a 
mannose main chain 
(β-1,4-
mannopyranose) 
with galactose side 
chains.  These NSP 
are typically isolated 
Figure 2: β-galactomannan structure 
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from the endosperm of leguminous plant seeds or microbial sources.48  The 
diversity of galactomannans varies based on the galactose:mannose ratio 
(gal:man) with galactose molecules specifying the solubility of each source.49  
Table 1 shows the gal:man ratio of various galactomannan gums and sources.  
Several industries, including the food industry, rely on the important chemical 
properties of galactomannans to promote thickening, gelling, binding, 
emulsifying, increased water holding capacity, and suspension.48  Animal feed 
ingredients, including soybean meal (SBM), also contain β-GM in sufficient 
quantities (1.02-1.51%) to be implicated in reduced weight gain, diminished 
performance, and impaired absorption of glucose and water in poultry.50  Similar 
detrimental consequences of dietary β-GM have also been shown in swine.51,52   
 
Consumption of β-Galactomannan elicits an immunogenic immune 
response  
 
 NSPs, including galactomannan, are produced by leguminous plants and 
extracellularly by pathogenic microorganisms to enhance their virulence.53  
Therefore, it is completely reasonable to hypothesize that oral administration of 
plant derived β-GM will possess immunogenic properties.  Indeed the literature to 
date has indicated strong immunostimuatlory effects of mannan polysaccharides. 
Of particular medical importance, acemannan reportedly reduces mortality rates 
of sarcomas in mice and stimulates DC maturation and subsequent T cell 
activation required to fight infection and disease.54.55  Galactomannans also 
induce the production of innate inflammatory cytokines, including IL-12, IL-6, and 
IFN-γ, and cause DC maturation.56   
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 It is of great importance to maintain balance when it comes to the 
gastrointestinal immune system.  The GIT is constantly exposed to both 
pathogenic and non-pathogenic materials and is responsible for mounting the 
proper immune response.  Eliciting an inflammatory response against harmless 
antigens, such as plant derived β-GM, is detrimental and causes several 
destructive side effects when chronically activated.  Disruption to the epithelial 
barrier, impaired nutrient absorption, and reduced growth due to nutrients being 
partitioned to support the immune response are potential mechanisms.57,58   
 Dendritic cells can sample luminal contents for dietary factors, such as 
galactomannan, which causes antigenic or immunogenic responses by opening 
tight junctions between epithelial cells, antigen direct entry into the Peyer’s 
patches through M cells, or transportation of antigen directly into the lamina 
propria.  In fact, Rescigno et al.59 found that expression of DC transepithelial 
projections increased when bacteria were present.  Galactomannan is 
recognized by PRRs but the exact PRR galactomannan signals through remains 
unclear.  Some researchers speculate cross-talk between TLRs and C-type lectin 
receptors (CTLs) are required for the immune repsonse.60  CTLs are 
carbohydrate recognition domains able to recognize subtle differences in 
arrangement and branching of carbohydrates.60 The main function of CTLs is to 
internalize pathogens for degradation and enhance antigen processing and 
presentation.61  CTLs are thought to promote tolerance by inducing Treg and Th2 
production.62 Geijtenbeek et al.63 demonstrated that when antibodies were used 
to block the DC-SIGN, a CTL, tolerance was compromised and proinflammatory 
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IL-12 concentrations were restored. TLRs are able to recognize foreign 
carbohydrate structures and initiate an intracellular signaling pathway (i.e., the 
MyD88 pathways), which can lead to production and secretion of inflammatory 
cytokines. Communication between TLRs and CTLs may be critical for immune 
tolerance and activation. When a foreign antigen binds concurrently to CTLs and 
TLRs, the TLR can override the tolerant effect of the CTL and evoke an immune 
response, even if the antigen is innocuous galactomannan found in food.63   After 
TLR and CTL activation, intracellular signaling leads to the production of 
proinflammatory cytokines IL-12, IL-6, IL-1, TNF-α and chemokines.55 This innate 
response causes acute inflammation in the gut characterized by infiltration of 
leukocytes and other immune modulators into the tissue.   
 Dendritic cells also trigger the adaptive immune response.  After TLR 
signaling occurs, DCs increase expression of MHC for antigen presentation, and 
increase the production of co-stimulatory molecules, IL-12, adhesion molecules, 
chemokine receptors, and have diminished ability for antigen phagocytosis.64,65,55  
Mature DCs migrate via lymph to the MLN and induce differentiation of naïve 
CD4+ cells into effector T cells, Th1 and Th17, to assist in clearing the infection. 
 
Consequences of intestinal inflammation 
  
 Persistent insults to the gut epithelia, such as continuous intake of 
galactomannan, may result in a long-term inflammatory state known as chronic 
inflammation. Numerous studies have reported on the inverse correlation 
between inflammation and body weight.17  Several mechanisms have been 
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implicated as the root cause of the decrease in weight gain during periods of gut 
inflammation.  Kanno et al.66 showed villous atrophy in histological samples 
collected from swine undergoing immune challenge.  Because the villi are 
essential for effective nutrient absorption, compromised uptake of nutrients was 
likely.  Indeed, measures of glucose, sodium, and chloride transport indicated all 
to be significantly reduced. This reduction of nutrient absorption may exaggerate 
catabolic pathways in the host leading to reductions in weight gain or even 
weight loss. Furthermore, compromised nutrient absorption may be coupled with 
repartitioning of nutrients away from growth to support immunological 
pathways.57  Finally, another contributor to suppressed weight gain during 
inflammation is the direct regulation of metabolic pathways by certain 
proinflammatory cytokines such as TNF-α and IL-6.  One study administered 
inflammatory cytokines to rats at physiological levels which led to altered 
consumption and consequently weight loss.67   
 A more detrimental effect of intestinal inflammation can lead to various 
pathologies.  Chronic stimulation of TLRs in gut epithelial cells and leukocytes 
can cause a decrease in epithelial cell migration and proliferation resulting in 
aberrant intestinal restitution.68  In TLR4 knockout mice, enterocyte apoptosis 
rates were ameliorated, which implicates this PRR in intestinal cell apoptosis.68 
When IECs become apoptotic, barrier integrity is compromised leaving hosts 
susceptible to pathogenic material and opportunistic commensals.57  Invasion of 
these microorganisms exacerbates inflammation in order to protect the host but 
this protective response only further disrupts intestinal integrity and creates a 
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vicious cycle.  It is possible, as has been demonstrated in the literature, that 
plant-derived galactomannan provokes superfluous innate immune responses 
and inflammation.47  Regular consumption may cause chronic inflammation and, 
as previously noted, lead to epithelial damage and defects. 
 
Therapeutic effects of mannans 
 Cancer and cancer treatments, such as chemotherapy, can significantly 
weaken the immune system which is a critical component needed to help fight 
diseases associated with tumors.  It seems logical to hypothesize that the 
inflammatory effects observed during mannan administration may help boost the 
immune system in times of need.  Immunomodulator acemannan has been 
researched extensively for its ability to activate the immune system.  Bacterial 
LPS is commonly used to treat tumors but its use also results in unfavorable side 
effects such as pyrogen-associated toxemia, otherwise known as toxic shock 
syndrome.69 Studies reveal LPS and acemannan both stimulate production of 
inflammatory cytokines IL-1 and TNF-α with acemannan having a more powerful 
effect.70  Compared to control mice, acemannan treated mice presented greater 
tumor regression which could be due to the stimulatory effects of inflammatory 
cytokines.70   
 The seed Fenugeek contains galactomannan that may possess anti-
diabetic properties.  Evans et al.71 found fenugeek consumption inhibited glucose 
absorption and other studies revealed that fenugeek galactomannan decreased 
the post-prandial glucose response.72   
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 Clinical use of a non-toxic, plant derived therapeutic agent to treat 
pathologies is a promising alternative to toxic medications currently used to fight 
different disease states.  Although the therapeutic effects of mannans are 
promising, contradictory evidence is present in the literature.  Some studies show 
no significant therapeutic effect of mannans.  The different outcomes of mannan 
consumption may be due to variances in structure such as the 
galactose:mannose ratio in various galactomannan sources.  Further 
investigation is required to fully elucidate its therapeutic effects. 
 
Enzymatically modified β-GM may have anti-inflammatory effects and 
promote tolerance 
 
 Humans and other species lack the enzymes necessary to digest the non-
starch polysaccharide β-GM but this altered structure can alleviate the 
immunogenicity of the antigen and is necessary to induce anti-inflammatory 
effects and promote a tolerogenic environment.73  The animal industry developed 
particular interest in β-GM and its adverse effects in livestock such as swine and 
poultry.  Some researchers found β-mannanase, an enzyme capable of digesting 
β-GM, is capable of increasing lean gain and average daily gain compared to 
their counterparts who did not consume a feed with the added enzyme.52  Due to 
conflicting data, the effects of β-mannanase in livestock remains unclear. 
 Partially hydrolyzed guar gum (PHGG) supported an anti-inflammatory 
environment revealed by statistically lower levels of IgG in MLNs and reduced 
IgA levels in serum, compared to guar gum (GG).74  Pre-feeding rats PHGG 
diminished protein and mRNA levels of the inflammatory cytokine TNF-α after 
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being administered DSS to induce colitis.  Weight loss and reduced infiltration of 
immune cells were also observed which supports the hypothesis that PHGG 
restrains the mucosal inflammatory response.75   
It is possible that enzymatically digested β-GM promotes a tolerogenic 
environment by preventing maturation of immature DCs and differentiation of 
Tregs from naïve T cells.  Immature dendritic cells are highly capable of antigen 
uptake.  During steady state conditions in the gut there is lack of inflammatory 
signals, such as inflammatory cytokines and chemokines.76  Recognition of 
dietary or self antigens by the PRRs (TLRs and CLRs) of the dendritic cell 
triggers an intracellular signal that leads to the translocation of the transcription 
factor NF-κB to the nucleus which promotes synthesis of IL-10 mRNA.  This anti-
inflammatory cytokine is critical for promoting tolerance in the gut and other host 
tissue.  In this scenario, low amounts of IL-12, an inflammatory cytokine, are 
produced and secreted.  Release of IL-10 by immature DCs has an autocrine 
effect and blocks maturation of the immune cell, which is characterized by 
reduced expression of MHCII, costimulatory molecules, adhesion molecules, and 
IL-12 production.77  It has been demonstrated that DCs, in the presence of IL-10 
antibodies, matured and became capable of activating naïve T cells to develop 
into effector T cells eliciting an immunogenic response.78 The secreted IL-10 is 
also an important signaling molecule in adaptive immunity for the differentiation 
of naïve T cells into IL-10 producing iTregs upon antigen presentation. TGF-β is 
another immunosuppressive and anti-inflammatory cytokine produced by 
immature DCs and iTregs. 
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Modulated dendritic cells travel to the MLNs to promote T cell anergy or 
apoptosis while also inducing Treg production.  The immature dendritic cells 
present the harmless antigen on MHCII to a naïve CD4+ T cells receptor in the 
presence of IL-10 and TGF-β.  The result is production of IL-10 or TGF-β 
secreting iTregs.  Induced Tregs can suppress immune cells, which supports gut 
homeostasis and tolerance.78  IL-10, secreted from any immune cells or IECs, 
inhibits maturation of DCs leading to the conversion of immunogenic DCs to 
tolerogenic DCs.79   
Plenty of research has yet to be completed in order to pinpoint the exact 
mechanism enzymatically digested β-GM promotes tolerance but the above 
pathways appear to be a sound hypothesis. 
 
Roles of IL-10 in immune tolerance 
Interleukin-10 (IL-10) is a pleiotropic cytokine with both 
immunosuppressive and anti-inflammatory effects.  Several leukocytes and 
lymphocytes can produce and secrete IL-10 such as monocytes, macrophages, 
T cells, and dendritic cells.  IL-10 secretion can dampen the immune system and 
prevent excessive collateral damage during times of immunogenic challenge and 
promote a tolerogenic environment upon host exposure to harmless antigens. 
Preliminary research has revealed that administration of IL-10 as a therapeutic 
agent is 100 times more efficient than Cyclosporin A, a common 
immunosuppresor.80 Absence of IL-10 causes uncontrolled chronic inflammation 
and impairs tolerance to dietary and self antigens.81  IL-10 knockout mice 
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presented chronic IBD, anemia, and compromised growth rates compared to 
wild-type mice.81  These deleterious outcomes, to a lesser extent, were even 
present in IL-10 knockouts housed in a germ-free environment highlighting the 
importance of IL-10 in the tolerance of normal enteric antigens.  Injections of IL-
10 ameliorated inflammation, weight loss, and improved survival rates.  
 Mechanistically, IL-10 has both direct and indirect effects on many 
immune cells. In the case of antigen specific T cell differentiation and 
proliferation, IL-10 can directly inhibit the production of IL-2, a cytokine 
responsible for the proliferation of activated T cells.79  IL-10 can also indirectly 
affect naïve CD4+ T cell activation by downregulating APC expression of MHCII, 
adhesion molecules, and costimulatory molecules (CD40, CD80, CD86).64,82  
Inflammatory cytokine and chemokine production is repressed by IL-10.  Without 
co-stimulatory molecules, inflammatory cytokines such as IL12, and chemokines 
migration and activation of T-cells will not occur.  Suppression of DC IL-12 
production by IL-10 prevents stimulation of NK cells and impairs Th1 
development in the periphery.83 Presence of IL-10 modulates DCs and promotes 
a tolerogenic function.  These tolerogenic DCs (tDCs) produce low levels of 
inflammatory cytokines and high levels of anti-inflammatory cytokines, 
particularly IL-10.84 tDCs interact with naïve T cells in the lymph nodes leading to 
anergy, apoptosis, or induction of Tregs. 
 IL-10 also exerts its effects on non-immune cells such as the goblet cells 
of the intestinal tract, which are responsible for producing mucins, an important 
component of mucus.  During an inflammatory challenge, defective folding of 
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proteins may occur leading to endoplasmic reticulum (ER) stress and activation 
of the unfolded protein response (UPR) and exacerbation of intestinal 
inflammation.  Chronic ER stress in goblet cells disrupts mucin production 
therefore depleting the protective mucus barrier of the epithelium.85  IL-10 
maintains mucin secretion by promoting correct protein folding, which 
suppresses ER stress and UPR activation.85  UPR transcription factor ATF6 
translocation to the nucleus is blocked by IL-10 signaling.86 
 
Prebiotic role of hydrolyzed galactomannan 
 
 The use of probiotics and prebiotics to improve gut health has become 
increasingly popular among Americans.  Prebiotics, which are typically non-
digestible oligosaccharides, are utilized by microbiota of the GIT to promote 
growth of selected beneficial bacteria.  Appropriate microbial members of the 
intestine, such as lactobacillus and bifidobacterium, of the intestine displace 
undesirable microflora, inhibit pathogens, and improve immunological status of 
the host.87-89  Clinical studies have revealed administered partially hydrolyzed 
guar gum, prebiotic galactomman, increased bifidobacterium concentrations in 
feces in comparison with control feces and significantly increases 
lactobacillus.90,91   
 Commensal gut microbiota are capable of preventing pathogen 
attachment to epithelial cell and may do so by acting as receptor decoys on 
intestinal epithelial cells.92  Consequently, the host can excrete this pathogen-
prebiotic complex.  Shoaf et al.92 tested numerous prebiotic oligosaccharides and 
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their ability to reduce adherence of Escherichia coli in vitro.  Galactomannan 
oligosaccharides prohibited Escherichia coli adherence to epithelial cells to the 
greatest extent in comparison to other prebiotic oligosaccharides.92  Other 
pathogens such as, Salmonella enterica, also elicit an immune response upon 
attachment characterized by production of inflammatory cytokines and 
chemokines.  Prebiotic galactomannan treatment reduced IL-6 and CXCL8 
production by 40% and 30%, respectively, compared to negative control cultures 
of medium.93  Using natural prebiotic galactomannan to improve gastrointestinal 
health is an exciting and intriguing area of research that will hopefully lead to 
reduced reliance on clinical medications that can cause adverse side effects and 
toxicities. 
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CHAPTER 2: IMPACT OF PLANT DERIVED β-GALACTOMANNAN ON 
HEALTH AND IMMUNE STATUS OF SPRAGUE-DAWLEY RATS 
 
 
 
Abstract 
 
 Intestinal inflammation triggered by dietary antigens or immunogens is an 
energy draining physiological process that compromises gut function and health. 
Guar gum, a common food additive, contains β-galactomannan, which is also 
found on the surface of many microbial pathogens.  Previous studies, both in vivo 
and in vitro, have shown β-galactomannan possesses immunostimulatory 
capabilities. In livestock, β-galactomannan reduced weight gain, impaired nutrient 
absorption, and increased inflammatory cytokines.  In this study, male Sprague-
Dawley rats received either the control diet or the experimental diet containing 
guar gum β-galactomannan (100g/kg) in place of cellulose.  After 3, 7, 14, and 21 
days rats were sacrificed and the small intestine was collected for analysis.  Rats 
receiving β-galactomannan gained significantly less weight  (9.4%; p<0.05) and 
exhibited reduced food intake compared to control rats (12.3%; p<0.05).  Based 
on previous studies it was expected that this result was owing to an inflammatory 
state; however, mRNA abunance of inflammatory cytokines IL-12a, IL-12b, and 
IL-6 in the ileum were not affected by β-galactomannan consumption.  Moreover, 
the anti-inflammatory cytokine IL-10, as well as Unfolded Protein Response 
(UPR) markers ATF-6 and PERK were without effect.  Contrary to our 
hypothesis, β-GM increased IL-10 and decreased IL-12 mRNA abundance in the 
jejunum.  Based on our study, guar gum β-galactomannan reduced overall 
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weight gain and dietary intake in rats, but did not invoke an innate immune 
response. 
 
Introduction 
 
Dietary antigens and immunogens can cause gut inflammation, and if 
chronic or repeated exposures occur, gut function and health become 
compromised.  Locust bean gum, guar gum, tara gum and fenugreek gum are 
common industrial food additives used primarily as thickeners, binders, and 
stabilizers.94  These seed gums are a major source of β-galactomannan (β-GM), 
a non-starch polysaccharide (NSP) composed of a β-(1,4)-mannan backbone 
with α-(1,6) side chains.  The galactose to mannose ratio is variable between 
galactomannan sources leading to various functional properties.  Animal 
studies46,49,51,52 indicate that β-galactomannan may contribute to the anti-
nutritional aspects of soybean products which include inflammation and 
diminished growth and nutrient utilization.  Furthermore, there are indications that 
Ig profiles may be altered in animals consuming guar gum54.  These studies 
underscore a key question regarding dietary β-galactomannan, that being 
whether consumption of this NSP induces an innate immune response and 
invokes a pro-inflammatory response in the gut.  Due to their commercial use 
and prevalence in microbial sources, it is important to characterize and 
understand the immunological effects and health consequences of 
galactomannan consumption.  Consequently, the aim of the present study was 
two-fold.  First, we sought to test the hypothesis that consumption of significant 
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quantities of β-GM (provided as guar gum) invokes an innate immune response 
and promotes inflammation in the gut, and reduces feed intake and growth in 
rats.  Secondly, we determined whether gastrointestinal disturbances associated 
with consumption of guar gum were linked with increased expression of markers 
of the unfolded protein response (UPR).  
 
Materials and Methods 
 
Animals.  All protocols were approved by the Institutional Animal Care and Use 
Committee and performed according to Iowa State University Laboratory Animal 
Resources Guidelines.  Six-week-old male Sprague-Dawley rats (N=96; Harland 
Teklad, Indianapolis, IN) were obtained at 148-171 grams.  Rats were singly 
housed in plastic cages in a room with a 12 hour light-dark cycle, and given ad 
libitum access to food and water.  The experiment was carried out with two 
replicate groups of rats started on dietary treatments 3 weeks apart.  The rats 
were maintained on a soy free pellet until started on experimental diets (see table 
2.1).  Each treatment group within replicate was further divided into four groups 
that were indicated by days on diets until sacrifice: day 3 (n=7), day 7 (n=7), day 
14 (n=7), and day 21 (n=7).  The second trial of mice (n=40) were fed a the same 
generic soy pellet diet but were acclimated for four weeks before being randomly 
divided into the two dietary treatment groups (control n=20, β-GM n=20) and 
assigned to a sacrifice time: day 3 (n=5), day 7 (n=5), day 14 (n=5), and day 21 
(n=5).  On their respective sacrifice days, rats were fasted for six hours before 
being euthanized by CO2 asphyxiation for sample collection.  Whole blood was 
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obtained immediately via cardiac puncture and centrifuged for isolation of 
plasma.  Small intestine, spleen, and epididymal fat pad tissue was collected and 
frozen on dry ice prior to storage at -80oC. 
 
RNA extraction and isolation.  RNA was isolated from the ileum and jejunum a 
using Quick Gene RNA tissue kit SII (Kurabo, Osaka, Japan).  The 
manufacturer’s instructions were followed with minor changes.  A small amount 
of tissue was pulverized using liquid nitrogen, a mortar bowl and pestle.  A pea-
sized amount of the crushed tissue was place in a tube containing 500 µl of LRT 
and β-mercaptoethanol mixture.  Samples where then homogenized using a 
standard sonicator for 30 seconds and then centrifuged for three minutes at 
17,000 x g.  The centrifuge step was completed at room temperature.  Following 
centrifugation, 385 µl of supernatant was removed from samples and transferred 
into a new tube.  After the transfer, 175 µl of SRT was added and samples were 
vortexed for 15 seconds.  Next, 140 µl of 99% EtOH was added to the tube and 
subsequently vortexed again for 1 minute.  Samples were pipetted into cartridges 
and placed into a QuickGene-810 Autogen (FujiFilm, USA) for further processing.  
Trace DNA was removed from RNA using a TURBO DNA-freeTM kit (Invitrogen, 
Carlsbad, CA).  To determine the concentration and purity of RNA samples, the 
NanoDrop ND-1000 Spectrophotometer was used. 
 
cDNA synthesis and quantitative real-time PCR.  First strand cDNA was made 
in a 20 µl mixture using a BioRad iCycler.  First, 1 µl RNA, 1 µl 10 mM dNTP mix 
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and distilled water to 12 µl.  Mixture was heated to 65oC for 5 minutes and chilled 
on ice.  4 µl 5x First-Strand buffer, 2 µl 0.1 M DTT, and 1 µl RNaseOUTTM 
Recombinant Ribonuclease Inhibitor was added to the initial mixture and gently 
mixed.  Mixture was incubated at 37oC for 2 minutes.  Following incubation, 1 µl 
of M-MLV Reverse Transcriptase was added and the resulting mixture was 
incubated at 37oC for 50 minutes followed by an inactivation step for 15 minutes 
at 70oC. 
 Quantitative real-time polymerase chain reactions (qPCR) were performed 
using Roche Light Cycler 96 in triplicates.  Each 20 µl PCR mixture contained 10 
µl Fast Start Essential DNA Green Master 2x concentration (Roche), 100µM 
forward primer (Integrated DNA Technologies), 100µM reverse primer (Integrated 
DNA Technologies), 8 µl RNase free water, and 1 µl of cDNA.  The 40 cycle 
amplification protocol consisted of an initial denaturation at 95oC for 10s, followed 
by 10s annealing step at 56-60oC, depending on gene, and extension at 72oC for 
10s. 
 
Statistics.  Statistics were calculated using the SAS 9.4 software (SAS, Cary, 
NC).  Data from both replicates were combined for analysis unless otherwise 
noted.  Means of treatment group were compared to control using the student’s t-
test.  Differences were considered significant at p<0.05 and a tendency at 
p<0.10. 
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Results 
 
β-galactomannan supplementation lowered total weight gain and total feed 
intake.  Rats receiving the β-GM diet gained, on average, 9.4% less weight than 
control rats (p<0.05, Fig. 1A).  However, total feed intake of rats consuming β-
GM was also significantly reduced (p<0.05) by about 12% (Fig. 1B). 
 
β-galactomannan reduced dietary intake throughout the 21 day experiment.  
Analysis of the interaction between diet and sacrifice day revealed rats fed β-GM 
regularly ate less than control rats during the duration of the study.  Rats fed β-
GM consumed less than rats fed the control diet (p<0.05, Figure 2).  On day 
fourteen we observed the biggest discrepancy in feed intake between treatments 
revealing rats consuming β-GM ate 36g less. By day 21 the difference in feed 
intake between the two groups decreased to 28g, roughly.  Diet x sacrifice day 
interaction p<0.10. 
 
Dietary treatment did not change cytokine mRNA abundance in the Ileum.  
β-GM did not impact anti-inflammatory IL-10 mRNA levels (Fig. 3A).  Likewise, 
transcript abundance of inflammatory cytokines IL-6, IL-12a, and IL-12b were not 
affected by β-GM treatment (Fig. 3B, 3C, 3D). 
 
Diet did not affect ileal mRNA abundance of transcription factors PERK and 
ATF-6.  Although it appears β-GM decreased mRNA abundance of the 
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transcription factors PERK and ATF-6 not significant differences were identified.  
β-GM did not alter PERK or ATF-6 mRNA levels (Fig. 4). 
 
β-GM treatment reduced jejunum IL-12a mRNA transcript abundance. 
Analysis of mRNA transcript abundance for IL-12a in the jejunum revealed 
significant alterations in rats fed β-GM relative to control rats (p<0.05) (Fig. 5).  β-
GM supplementation resulted in lower mRNA levels of IL-12a. 
 
Neither dietary treatment significantly impacted IL-12b transcript 
abundance in the jejunum of rats.  Although the data suggests β-GM 
increased abundance of IL-12b mRNA, analysis revealed no significant 
differences between dietary groups (Fig. 6). 
 
IL-10 transcript abundance in the jejunum was greater in rats fed β-GM 
compared to control rats.  Data for IL-10 transcript abundance revealed 
increased IL-10 mRNA levels in the jejunum of rats fed β-GM.   
 
Discussion 
 
 β-GM has been associated with unnecessary immune system stimulation 
and subsequent weight loss; however, the current literature is controversial and 
scarce.  Here, we hypothesized that consumption of β-GM would trigger an 
unwarranted innate immune response. 
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 Dendritic cells (DCs) are capable of monitoring luminal contents and 
orchestrating a tolerogenic or immunogenic immune response. Depending on the 
intestinal micromileu, subtype, and maturation, DCs and their cytokine profile 
induce differentiation of naïve CD4+ T-cells into immunogenic (Th1, Th2, Th17) 
or tolerogenic (Treg) T-cells.95  Research shows NSPs, which are innocuous food 
antigens, may evoke a superfluous inflammatory immune reaction which has 
been characterized by enhanced macrophage activation, increased NF-κB 
expression, raised levels of serum IgA, and high IgG and IgM activity in 
mesenteric lymph nodes.47,52,74  Because inflammation is an energy draining 
process, nutrient partitioning favors immunological processes instead of anabolic 
pathways which often leads to decreases in body weight due to wasting.16  
Persistent inflammatory insults to gut epithelial have also been shown to cause 
villi atrophy and consequently impaired nutrient absorption, ER stress, increase 
autophagy of mucosal cells, reduced brush border enzyme activity, aberrant 
intestinal restitution, compromised barrier integrity, and susceptibility to 
pathogenic and opportunistic commensals.58,66,68,96  In livestock, studies have 
demonstrated that by enzymatically breaking down  β-GM in soybean meal with 
β-mannase, fewer β-GMs are able to induce an immune response and adverse 
side effects are alleviated.52,97,98	  
 Inflammatory cytokines are a hallmark of the innate immune response and 
have been shown to be produced after β-GM is recognized by PRRs on DCs and 
macrophages.99  The resulting immunogenic DC can induce effector T-cell 
differentiation.  Inflammatory cytokines are necessary T-cell induction and for 
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recruiting inflammatory cells the site of infection.  As immune cells aggregate, 
even more inflammatory cytokines are generated along with reactive oxygen 
species (ROS).  Both these factors are capable of activating endoplasmic 
reticulum (ER) stress in mucosal cells and consequently the unfolded protein 
response (UPR).100  PERK and ATF-6 are two important genes involved in 
regulating the UPR.85,86  Based on this concept, it would be expected that the 
mRNA abundance of both transcription factors would be elevated in rats fed β-
GM.  However, our data reveals no significant differences between dietary 
treatments. 
 Livestock studies have consistently documented decreased weight gain in 
β-GM feeding studies.  This inverse relationship between β-GM and growth 
inhibition is rational considering the adverse effects the inflammatory response 
has on intestinal epithelium.  Any damage to barrier function, such as reduced 
villi height, can lead to malabsorption of key nutrients and most of the nutrients 
that still get absorbed will be utilized by the body to provide energy for 
immunological processes.  Our study shows consumption of β-GM reduced total 
weight gain in rats by ~11% which is exactly what we had expected.  Further 
analysis of our data revealed that β-GM also reduced total feed intake by ~12%.  
It is difficult to determine if the β-GM-mediated weight reduction is actually due to 
inflammation caused by β-GM or if an unfavorable taste of β-GM resulted in 
decreased food intake and consequently reduced weight gain.  The largest 
difference in food intake occurred on day 14, where control rats, on average, 
were consuming ~16% more than those receiving the β-GM diet.  This 
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discrepancy in dietary intake may be the result of innate immune responses in 
rats fed β-GM.   
 If inflammation is actually the culprit affecting weight reduction in this 
study, it is reasonable to assume inflammatory cytokine (IL-6, IL-12a, IL-12b) 
transcript abundance would be higher in rats fed β-GM and the anti-inflammatory 
cytokine IL-10 would be lower.  Contrary to our hypothesis and existing literature, 
there was no diet effect on any cytokine (IL-6, IL-12a, IL-12b, IL-10) mRNA 
abundance in the ileum.  Even more perplexing was that we observed significant 
changes in jejunum cytokine mRNA between diet groups and the results are 
opposite of what we anticipated.  IL-12a transcript abundance decreased in rats 
fed β-GM whereas IL-10 increased.  Previous literature reports the β-GM 
increases inflammatory cytokines and decreases anti-inflammatory cytokines.47  
This suggests its likely that β-GM is captured by C-type lectin receptors (CTLs) 
such as Mannose receptor (MR) and DC-SIGN.101  When MR and DC-SIGN 
recognize high mannose containing antigens, such as β-GM, the dendritic cell 
will capture and present them without activating the cell.102  CTLs may also 
interfere with TLR signaling and as a result inhibit DC maturation.102 
Various studies have shown IL-10 is the primary cytokine produced 
following activation of MR and DC-SIGN on DC.101-104  The autocrine effect of IL-
10 on DCs modulates maturation resulting in tolerogenic DCs.  An alternative 
explanation for increased IL-10 and decreased IL-12a is that the elevated IL-10 
could be an adaptive response after prior exposure to β-GM in order to down 
regulate inflammation in the jejunum.  
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Future studies should consider using similar fiber types when comparing 
diet effect.  In our study, guar gum is a soluble fiber and cellulose, used in the 
control diets, is an insoluble fiber.  Because guar gum is soluble, it attracts water 
and will turn into a gel-like consistency during digestive processes.  This gel can 
slow gastric emptying and signal satiety causing the rat to consume less and 
may be way our guar gum fed rats weighed less than rats fed the control diet. 
 Overall, our study showed inflammatory cytokine and UPR transcription 
factor mRNA abundance was not significantly increased in rats consuming β-GM.  
We can therefore conclude, from these inflammatory markers, there is no 
inflammatory response associated with β-GM intake.  In the jejunum, β-GM 
surprisingly increased anti-inflammatory cytokine IL-10 transcript abundance.  
Cytokine IL-10 could possibly promote tolerance in the jejunum.  Although, our 
study contradicts present research, it should be noted many of the experimental 
designs use mannans or galactomannans of different configurations from 
sources other than guar gum which could account for the variances in immune 
response. 
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Table 1: Galactose to mannose ratio of different galactomannan  
 
 
 
Table 2: Ingredient composition of the control and β-galactomannan diets 
fed to rats 
 
Source Gal:Man Ratio 
Guar gum 1:1.7 
Soybean meal 1:1.8 
Fenugreek gum 1:1.1 
Carob bean gum (Locust bean gum) 1:3.5 
Tara Gum 1:3.0 
Componentsa Control diet (g/kg) β-GM diet (g/kg) 
Sucrose 100.0 100.0 
Maltodextrin 132.0 132.0 
Corn Starch 327.5 327.5 
Casein 200.0 200.0 
Cellulose 100.0 0.0 
Guar Gum 0.0 100.0 
Corn Oil 90.0 90.0 
Premixb 50.5 50.5 
a  All diet ingredients were purchased from Harlan Teklad (Madison, WI), choline 
bitartrate (Sigma Aldrich). 
b  Premix provided at 50 g/kg diet (g/kg diet): AIN-93 vitamin mix, 10; AIN-93 
mineral mix, 35; L-Cystine, 3; Choline Bitartrate, 2.5; TBHQ, 0.014. 
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Figure 1: β-galactomannan supplementation causes reduced weight gain 
and reduced dietary intake. Male Sprague-Dawley rats (N=96) were randomly 
assigned to two different experimental replicates: Replicate 1 (n=56), Replicate 2 
(n=40).  Rats in each replicate received a control diet or a diet containing beta-
galactomannan (100g/kg).  Rats in both dietary groups were randomly assigned 
one of four sacrifice days (day 3, 7, 14, 21). Bars represent pooled data from rats 
in replicate 1 and replicate 2. Values shown are group means ±SE.  Asterisk 
indicates significant difference in group mean when compared to the control 
using a student’s t-test (p<0.05). 
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Figure 2:  Rats fed β-GM ate less throughout the three weeks study 
compared to control mice. Male Sprague-Dawley rats (N=96) were randomly 
assigned to two different experimental trials: Replicate 1 (n=56), Replicate 2 
(n=40).  Rats in each replicate received a control diet or a diet containing beta-
galactomannan (100g/kg).  Rats in both dietary groups were randomly assigned 
one of four sacrifice days (day 3, 7, 14, 21). β-GM reduced dietary intake 
throughout the course of the 21 day experiment. The largest discrepancy in 
dietary intake occurs on day 14.  Rats consuming β-GM ate ~36g less than 
control rats on day 14.  Values shown are group means ±SE.  Asterisk indicates 
significant difference in group mean when compared to the control using a 
student’s t-test (p<0.05). Diet x sacrifice day interaction p=0.0858.  
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Figure 3: β-GM did not alter ileal IL-10, IL-6, IL-12a, or IL-12b transcript 
abundance.  IL-10 (A), IL-6 (B), IL-12a (C), IL-12b (D). Male Sprague-Dawley 
rats (N=96) were randomly assigned to two different experimental replicates: 
Replicate 1 (n=56), Replicate 2 (n=40).  Rats in each replicate received a control 
diet or a diet containing beta-galactomannan (100g/kg).  Rats in both dietary 
groups were randomly assigned one of four sacrifice days (day 3, 7, 14, 21). 
Bars represent pooled data from rats in replicate 1 and replicate 2. Means 
between the dietary groups were not statistically significant.  Values shown are 
group means ±SE.   
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Figure 4: β-GM did not alter ileum mRNA transcript abundance of the PERK 
or ATF-6.  Male Sprague-Dawley rats (N=96) were randomly assigned to two 
different experimental replicate: Replicate 1 (n=56), Replicate 2 (n=40).  Rats in 
each replicate received a control diet or a diet containing beta-
galactomannan(100g/kg).  Rats in both dietary groups were randomly assigned 
one of four sacrifice days (day 3, 7, 14, 21). Bars represent pooled data from rats 
in replicate 1 and replicate 2. Means between the two dietary groups were not 
statistically significant.  Values shown are group means ±SE.   
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Figure 5: β-GM treatment reduced jejunum IL-12a mRNA transcript 
abundance.  Male Sprague-Dawley rats (N=96) were randomly assigned to two 
different experimental replicates: Repliate 1 (n=56), Replicate 2 (n=40).  Rats in 
each replicate received a control diet or a diet containing beta-galactomannan 
(100g/kg).  Rats in both dietary groups were randomly assigned one of four 
sacrifice days (day 3, 7, 14, 21). Bars represent pooled data from rats in replicate 
1 and replicate 2. Values shown are group means ±SE.  Asterisk indicates 
significant difference in group mean when compared to the control using a 
student’s t-test (p<0.05). 
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Figure 6: Neither dietary treatment significantly impacted IL-12b transcript 
abundance in the jejunum of rats.  Male Sprague-Dawley rats (N=96) were 
randomly assigned to two different experimental replicates: Replicate 1 (n=56), 
Replicate 2 (n=40).  Rats in each replicate received a control diet or a diet 
containing beta-galactomannan (100g/kg).  Rats in both dietary groups were 
randomly assigned one of four sacrifice days (day 3, 7, 14, 21). Bars represent 
pooled data from rats in replicate 1 and replicate 2. Means between the dietary 
groups were not statistically significant.  Values shown are group means ±SE. 
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Figure 7:  IL-10 transcript abundance in the jejunum was greater in rats fed 
β-GM compared to control rats.  Male Sprague-Dawley rats (N=96) were 
randomly assigned to two different experimental replicates: Replicate 1 (n=56), 
Replicate 2 (n=40).  Rats in each replicate received a control diet or a diet 
containing beta-galactomannan (100g/kg).  Rats in both dietary groups were 
randomly assigned one of four sacrifice days (day 3, 7, 14, 21). Bars represent 
pooled data from rats in replicate 1 and replicate 2. Values shown are group 
means ±SE.  Asterisk indicates significant difference in group mean when 
compared to the control using a student’s t-test (p<0.05). 	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